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Background-—Advances in treatment for acute myocardial infarction (AMI) are likely to have had a beneﬁcial impact on the
incidence of and deaths attributable to heart failure (HF) complicating AMI, although limited data are available to support this
contention.
Methods and Results-—Western Australian linked administrative health data were used to identify 20 812 consecutive patients,
aged 40 to 84 years, without prior HF hospitalized with an index (ﬁrst) AMI between 1996 and 2007. We assessed the temporal
incidence of and adjusted odds ratio/hazard ratio for death associated with HF concurrent with AMI admission and within 1 year
after discharge. Concurrent HF comprised 75% of incident HF cases. Between the periods 1996–1998 and 2005–2007, the
prevalence of HF after AMI declined from 28.1% to 16.5%, with an adjusted odds ratio of 0.50 (95% CI, 0.44 to 0.55). The crude
28-day case-fatality rate for patients with concurrent HF declined marginally from 20.5% to 15.9% (P<0.05) compared with those
without concurrent HF, in whom the case-fatality rate declined from 11.0% to 4.8% (P<0.001). Concurrent HF was associated with a
multivariate-adjusted odds ratio of 2.2 for 28-day mortality and a hazard ratio of 2.2 for 1-year mortality in 28-day survivors.
Occurrence of HF within 90 days of the index AMI was associated with an adjusted hazard ratio of 2.7 for 1-year mortality in 90-day
survivors.
Conclusions-—Despite encouraging declines in the incidence of HF complicating AMI, it remains a common problem with high
mortality. Increased attention to these high-risk patients is needed given the lack of improvement in their long-term prognosis.
( J Am Heart Assoc. 2013;2:e000172 doi: 10.1161/JAHA.113.000172)
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I schemic heart disease (IHD) is a leading cause of heartfailure (HF), which often develops as a complication of
acute myocardial infarction (AMI).1,2 The occurrence of HF
after AMI is associated with a poor prognosis.1,2 However, the
treatment of AMI has improved dramatically in recent decades
with the advent of early reperfusion strategies including
percutaneous coronary intervention and evidence-based
pharmacotherapies.3–7 These advances in therapeutic inter-
ventions are likely to have had a beneﬁcial impact on the
incidence of and deaths attributable to HF complicating AMI,
although limited data are available to support this assumption.
Some studies have reported a reduced incidence of HF
following AMI,8–11 but other studies found an increasing
incidence over time that paralleled the decrease in mortality
after AMI.12,13 Similarly, the in-hospital case-fatality rate of
AMI has fallen dramatically over recent decades, whereas HF
complicating AMI continues to be associated with high short-
and long-term mortality.10,13–16 Given the poor prognosis
posed by new-onset HF after AMI, it is important to
investigate the contemporary trends in incidence and mortal-
ity outcomes of this serious complication during the most
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recent era of early invasive intervention and evidence-based
AMI management.
The objectives of the present study were (1) to investigate
the sex-speciﬁc temporal trends in incidence of HF in 20 812
patients aged 40 to 84 years hospitalized with an index (ﬁrst)
AMI in Western Australia (WA) between 1996 and 2007, (2) to
explore the clinical predictors of concurrent and late-onset HF
after AMI, and (3) to determine if short-term (28-day) and
1-year mortality associated with HF after ﬁrst AMI has
changed over recent decades.
Methodology
Study Design and Population
Since the 1970s data for all hospitalizations in WA including
principal and secondary (up to 20) discharge diagnoses have
been maintained in the Hospital Morbidity Data (HMD)
Collection, which is regularly audited for quality and accu-
racy.17 The HMD is routinely linked to the Mortality Registry
as part of the WA Data Linkage System using probabilistic
matching, which has >99% accuracy.17 Our study is a
population-based cohort using linked health data comprising
all WA residents aged 40 to 84 years who were admitted with
a ﬁrst AMI between 1996 and 2007 as a principal discharge
diagnosis. First AMI was deﬁned as occurring in a patient
without a hospital admission for an AMI among the 21
discharge diagnoses in the previous 10 years. Patients with
an HF history, which was deﬁned on the basis of any
HF hospitalization in the 10 years before the index AMI
admission, were excluded.
AMI, as the principal diagnosis, was based on International
Classiﬁcation of Diseases (ICD) codes 410x (ICD-9-CM), and
I21x (ICD-10-AM). Concurrent HF was deﬁned as HF that was
recorded during the index AMI admission and late-onset HF as
occurrence within 1 year after discharge. Heart failure was
identiﬁed in any of the 21 diagnosis ﬁelds by ICD codes 428x,
402.01, 402.11, 402.91, 404.1, 404.3, 425x, 518.4, 514,
391.8, and 398.91 (ICD-9-CM) and I50x, I11.0, I13.0, I13.2,
I42x, J81, and I01.8 (ICD-10-AM).
Deﬁnitions of Comorbidities and Interventions
Comorbidities were identiﬁed from principal or secondary
diagnosis ﬁelds within the 5 years before the incident
admission or, if coded in a secondary diagnosis ﬁeld, on the
incident admission. Comorbid conditions were identiﬁed by
the following ICD codes: ICD-9-CM 401-405 and ICD-10-AM
I10-I15 for hypertension; ICD-9-CM 250 and ICD-10-AM
E10-E14 for diabetes; 411-414x, I20x, and I22-I25 for other
IHD (excluding AMI); 427.3 and I48 for atrial ﬁbrillation; 585
and N18 for chronic renal failure; 430x-438x, 362.34, and
997.0 and I60-I69 and R47.0 cerebrovascular disease; and
440-444, 447, 448, and I70-I79 for peripheral vascular
disease. A Charlson Comorbidity Index, as a weighted
summary score, was also calculated for each person.18
Coronary artery revascularization procedures, either percuta-
neous coronary intervention (PCI) or coronary artery bypass
grafting, within 10 years before or concurrent with the index
AMI admission were identiﬁed from the linked HMD.
Validity of the WA HMD Coding
The coding for HF as a principal discharge diagnosis in the WA
HMD has been previously validated with a positive predictive
value of 92.4% for “deﬁnite” HF and 98.8% for a combined
“possible” and “deﬁnite” HF based on the Boston HF score.19
The use of ICD-9-CM code 410 to deﬁne AMI has been
validated in a local population.20,21 The use of a 10-year
look-back (clearance period) to exclude prior admissions for
AMI or HF has been used previously to improve identiﬁcation
of incident cases.22,23
Data Analysis
Index hospitalizations for AMI were divided into 4 equal
calendar periods—1996–1998, 1999–2001, 2002–2004, and
2005–2007—for comparison purposes. Patients were fol-
lowed until death (all-cause) or 1 year after the ﬁrst AMI
hospitalization, with the last day of follow-up ending on
December 31, 2007. All patients admitted from January 1,
1996, until before December 1, 2007, were included for
28-day survival analysis. For survival analysis to 1 year, only
patients admitted with an index AMI between 1996 and 2006
were included. For trends in 1-year survival, we restricted our
analysis to patients who survived ≥28 days from the date of
index AMI admission.
Categorical variables are presented as proportions and
continuous variables as meansstandard deviations or medi-
ans and interquartile ranges. The Pearson chi-square test was
used to test for differences in categorical variables and
ANOVA, the t test, or the nonparametric Mann–Whitney test
for continuous variables. Trends (in proportions) were
assessed using the Cochran–Armitage trend test.
Age- and sex-adjusted logistic regression models were
used to determine the odds ratios (ORs) of developing
concurrent or late-onset HF associated with baseline risk
characteristics and comorbidities. Multivariable logistic
regression models were used to determine predictors of
death within 28 days, with ORs and their 95% conﬁdence
intervals (CIs) reported. After ensuring that the assumption of
proportional hazards was met, multivariable Cox proportional
hazards regression models were used to determine hazard
ratios (HRs) and 95% CIs for survival to 1 year in 28-day
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survivors with HF modeled as a binary covariate (no HF,
concurrent HF). To assess the impact of concurrent and
late-onset HF together and to avoid an immortal time bias, we
performed a landmark analysis in which we classiﬁed patients
based on the occurrence of an intermediate event, namely,
nonfatal HF hospitalization before a landmark point.24 This
analysis then evaluated patient outcomes from the landmark
time through to the end of the follow-up period (1 year). We
chose 90 days as our primary landmark point because the
majority of incident HF cases (90.8%) occurred within 90 days
of the initial AMI. Temporal trends in survival for calendar
periods were determined using 1996–1998 as the base
(comparator) period. Test for survival trend was performed
with year modeled as a continuous variable in the regression
analyses. Multivariable models were fully risk-adjusted for age
and sex and for all potentially important covariates listed in
Table 1 irrespective of nominal statistical signiﬁcance. The
risk adjustment model used has been previously reported.25
Stratiﬁed analyses by HF diagnosis or sex were performed if a
signiﬁcant interaction was found between HF and calendar
period or HF and sex. Statistical analyses were done with SAS
version 9.1 and STATA version 10.
Ethics Approvals
Ethics approvals for this study were obtained from the Human
Research Ethics Committees of the University of Western
Australia and Department of Health, Western Australia.
Results
Descriptive data for the 20 812 patients (29.6% women)
with a ﬁrst AMI, stratiﬁed by the 4 calendar periods, from
1996–1998 to 2005–2007, are provided in Table 1. Although
the mean age and sex mix of the patients did not change,
there was an increasing frequency of several comorbidities
over the study period including hypertension, diabetes, and
IHD (excluding AMI). However, peripheral vascular disease
and cerebrovascular disease were less prevalent. The fre-
quency of coronary revascularization procedures, predomi-
nantly PCI, performed during the index AMI admission
increased from 17.4% to 43.2% over the study period
(P<0.001). However, patients with concurrent HF were less
likely to undergo a revascularization procedure during the
initial admission compared with their counterparts without
concurrent HF (19.9% versus 33.3%, P<0.001).
The overall prevalence of any HF up to 1 year post-AMI
decreased progressively over the observation period, from
28.1% to 16.5% (P<0.001), largely because of a decline in
concurrent HF, which comprised 75% of incident HF cases
(Table 1). By the last calendar period, the age- and
sex-adjusted OR of developing any HF within 1 year after
index AMI was 0.50 (95% CI, 0.44 to 0.55; P<0.001). Of those
who developed new HF within 1 year after index AMI
admission, 84.9%, 90.8%, and 95.0% had occurred by 30
days, 90 days, and 6 months, respectively.
Table 2 shows the baseline characteristics and clinical
predictors of patients who developed concurrent or late-onset
HF after a ﬁrst AMI. Patients who developed HF were
signiﬁcantly older and more likely to be female compared with
their counterparts without HF. After adjustment for age and
sex, signiﬁcant positive predictors of concurrent HF were
hypertension, diabetes, atrial ﬁbrillation, chronic renal failure,
and peripheral vascular and cerebrovascular disease, whereas
prior IHD was a negative predictor. Predictors of late-onset HF
were identical to those of concurrent HF except for chronic
renal failure.
The crude 28-day case-fatality rate in all AMI cases
declined signiﬁcantly over the observation period largely
because of the patients without concurrent HF, in whom
mortality declined from 8.4% to 3.2% (P<0.001; Table 1).
Patients with concurrent HF had an overall 3-fold higher
case-fatality rate relative to patients without concurrent HF,
and their 28-day mortality declined marginally over the
observation period, from 20.5% to 15.9% (P=0.047). The
overall 1-year mortality in 28-day AMI survivors with versus
without concurrent HF was 15.3% versus 3.6% (P<0.001), and
the overall 1-year mortality in 90-day AMI survivors with
compared with without incident HF was 10.9% versus 2.2%
(P<0.001; Table 1). There was no signiﬁcant change over the
observation period in crude 1-year mortality in 28-day and
90-day AMI survivors with or without incident HF (Table 1).
Men and women showed similar trends in the 28-day
case-fatality rate and crude 1-year mortality (data not shown).
Table 3 shows adjusted ORs for death at 28 days, and
Table 4 shows HRs for death between 28 days and 1 year and
between 90 days and 1 year, after adjustment for age, sex,
occurrence of HF, comorbidities, interventions, and calendar
periods. Concurrent HF had a signiﬁcant adverse impact on
mortality, with an adjusted OR of 2.2 for 28-day mortality and
an HR of 2.2 for 1-year mortality in 28-day survivors. In the
landmark analysis, occurrence of HF within 90 days of index
AMI was associated with an adjusted HR of 2.7 for 1-year
mortality in 90-day survivors. The adjusted OR for death at 28
days declined progressively over the observation period, with
a 60% lower risk of death for the whole cohort by the last
calendar period (trend P<0.001). A signiﬁcant concurrent
HF–calendar period interaction was identiﬁed for 28-day
mortality (P<0.001), with stratiﬁed analysis showing lesser
reductions in adjusted OR of death at 28 days over successive
calendar periods in patients with compared with those without
concurrent HF (Table 3). A signiﬁcant concurrent HF-sex
interaction was also identiﬁed for 28-day mortality (P<0.001),
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and stratiﬁed analysis showed that men with concurrent HF
had a higher adjusted OR for 28-day mortality compared with
women, with ORs of 2.75 (95% CI, 2.34 to 3.23) versus 1.58
(95% CI, 1.30 to 1.91), respectively (Table 3).
Table 4 shows that compared with the early survival gains,
there was no further decline in adjusted HR for death between
28 days and 1 year (trend P=0.27) and a signiﬁcant increase
in adjusted HR for death between 90 days and 1 year in the
last 2 calendar periods (trend P=0.02). Further stratiﬁed
analyses by sex or occurrence of HF were not performed
because the interaction terms were not signiﬁcant. PCI
performed during initial AMI admission was associated with
an adjusted OR of 0.43 (95% CI, 0.35 to 0.52; P<0.001) for
death at 28 days, an HR of 0.40 (95% CI, 0.31 to 0.51;
P<0.001) for death between 28 days and 1 year, and an HR of
0.35 (95% CI, 0.27 to 0.44; P<0.001) for death between 90
days and 1 year. There was no signiﬁcant interaction effect on
mortality between concurrent HF and PCI during index
Table 1. Characteristics of Patients, Aged 40 to 84 Years, With a First Acute Myocardial Infarction According to Period of
Hospitalization Between 1996 and 2007
Characteristics Total
Period
P Value1996–1998 1999–2001 2002–2004 2005–2007
Number of patients, n 20 812 4300 4714 5450 6348
Female sex, n (%) 6162 (29.6) 1297 (30.2) 1377 (29.2) 1598 (29.3) 1890 (29.8) 0.73
Age, meanSD, y 64.911.7 64.711.8 64.911.7 64.911.7 65.011.0 0.091
Comorbidities, n (%)
Hypertension 9789 (47.0) 1893 (44.0) 2042 (43.3) 2420 (44.4) 3434 (54.1) <0.001
Diabetes 4726 (22.7) 903 (21.0) 1012 (21.5) 1273 (23.4) 1538 (24.2) <0.001
Other ischemic heart disease 11 493 (55.2) 2101 (48.8) 2370 (50.3) 3025 (55.5) 3997 (63.0) <0.001
Atrial fibrillation 2585 (12.4) 494 (11.5) 565 (12.0) 707 (13.0) 819 (12.9) 0.07
Chronic renal failure 1093 (5.3) 228 (5.3) 223 (4.7) 296 (5.4) 346 (5.5) 0.33
Peripheral vascular disease 2302 (11.1) 657 (15.3) 570 (12.1) 549 (10.1) 526 (8.3) <0.001
Cerebrovascular disease 2876 (13.2) 756 (17.6) 739 (15.7) 681 (12.5) 700 (11.0) 0.001
Interventions, n (%)
Prior PCI or CABG 1179 (5.7) 204 (4.7) 272 (5.8) 313 (5.7) 390 (6.1) <0.001
Within index admission 6551 (31.5) 750 (17.4) 1149 (24.4) 1912 (35.1) 2740 (43.2) <0.001
PCI 5887 (28.3) 630 (14.7) 1015 (21.5) 1748 (32.1) 2494 (39.3) <0.001
CABG 698 (3.4) 127 (3.0) 144 (3.1) 175 (3.2) 252 (4.0) 0.011
Heart failure, n (%) 4406 (21.2) 1210 (28.1) 1060 (22.5) 1086 (19.9) 1050 (16.5) <0.001
Concurrent HF 3286 (15.8) 933 (21.7) 797 (16.9) 786 (14.4) 770 (12.1) <0.001
Late onset 1120 (5.4) 277 (6.4) 263 (5.6) 300 (5.5) 280 (4.4) <0.001
Deaths, n (%)
28-Day deaths* 1515 (7.3) 472 (11.0) 414 (8.8) 333 (6.1) 296 (4.8) <0.001
No concurrent HF 915 (5.3) 281 (8.4) 260 (6.6) 198 (4.3) 176 (3.2) <0.001
Concurrent HF 600 (18.3) 191 (20.5) 154 (19.3) 135 (17.2) 120 (15.9) 0.047
1-Year deaths in 28-day survivors†
No concurrent HF 519 (3.6) 113 (3.7) 133 (3.6) 166 (3.7) 107 (3.2) 0.54
Concurrent HF 376 (15.3) 122 (16.4) 95 (14.8) 96 (14.8) 63 (14.8) 0.77
1-Year deaths in 90-day survivors†
No HF in 90 days 304 (2.2) 69 (2.4) 78 (2.2) 88 (2.1) 69 (2.1) 0.82
HF within 90 days 315 (10.9) 87 (10.3) 83 (10.8) 91 (11.6) 54 (10.9) 0.87
CABG indicates coronary artery bypass grafting; HF, heart failure; PCI, percutaneous coronary intervention; SD, standard deviation.
*Patients who were admitted before December 1, 2007.
†Patients with 1-year follow-up from date of index admission.
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admission. Performance of coronary artery bypass grafting
during initial admission had no effect on 28-day mortality but
was associated with a lower adjusted HR of death at 1 year in
28-day survivors (HR, 0.37; 95% CI, 0.21 to 0.65; P<0.001)
and at 1 year in 90-day survivors (HR, 0.33; 95% CI, 0.19 to
0.58; P<0.001).
Discussion
We investigated all patients without prior HF hospitalized with
a ﬁrst AMI in Western Australia between 1996 and 2007. Our
ﬁndings indicate that the short-term case-fatality rate after
ﬁrst AMI and the incidence of HF declined substantially in
both men and women over this period. Despite these
encouraging trends, HF complicating AMI still occurs fre-
quently and has a major adverse impact on short-term and
long-term mortality.
The present study conﬁrms that HF is more likely to
complicate AMI in older persons, in women, and in people
with added comorbidities including diabetes, hypertension,
renal failure, and peripheral vascular disease.2,11,26–28 By
contrast, patients with prior IHD (excluding AMI) were less
likely to develop HF, possibly because they were more likely
to be on cardioprotective medications (eg, aspirin, b-blockers,
ACEIs, statins) at onset of AMI. However, the observed
temporal changes in comorbidities in our AMI cohort suggest
that this factor alone is unlikely to explain the decline in
incidence of HF.
In this population-based study, about 1 in 6 patients
developed HF concurrent with their index AMI admission, and
overall 1 in 5 had an HF discharge diagnosis within the ﬁrst
year after AMI. Previous estimates of the incidence of acute
HF complicating AMI have varied between 10% and 48%
depending on the type of study (population-based, registry, or
clinical trial), inclusion of patients with prior AMI or prior HF as
opposed to ﬁrst events, duration of follow-up, and the period
of the study.2,4,8–13,29 However, more recent popula-
tion-based studies from the United States10 and Sweden11
have reported a hospital incidence of HF after AMI in the
same range as our present study. Concordant with previous
studies,8,11,13,15 most cases of HF occurred acutely in relation
to the AMI or in the subsequent few months. However, it has
been observed that with increasing post-AMI survival, the
incidence of HF may actually rise over time.8,11,13 For
example, in a large cohort of elderly patients, HF developed
in three-quarters in the 5 years after their ﬁrst AMI, and this
proportion increased over time as peri-AMI mortality rates
declined.13
Importantly, the age- and sex-adjusted odds of developing
HF within the ﬁrst year after AMI declined by 50% over the
study period. Other observational studies have also revealed a
decline in the incidence of hospitalized patients with HF after
AMI beginning in the early 1990s.4,8–11 The declining
incidence of HF has occurred coincidently with the broader
application of evidence-based interventional and pharmaco-
logical treatments following AMI in recent decades.3–6 In a
Table 2. Baseline Characteristics and Risk Predictors of Concurrent and Late-Onset Heart Failure in Patients With a First Acute
Myocardial Infarction Between 1996 and 2007
Description No HF Concurrent HF Late-Onset HF
Odds Ratio for
Concurrent HF* P Value
Odds Ratio for
Late-Onset HF* P Value
Cases, n (%) 14 440 (78.1) 3025 (16.4) 1024 (5.5)
Age, y, median (IQR) 63 (54 to 73) 73 (65 to 79) 73 (64 to 79) 1.06 (1.06 to 1.07)† <0.001 1.05 (1.04 to 1.05)† <0.001
Female sex 4415 (26.9) 1307 (39.8) 440 (39.3) 1.24 (1.14 to 1.35)‡ <0.001 1.22 (1.07 to 1.41)‡ 0.003
Comorbidities, n (%)
Hypertension 6267 (43.4) 1632 (54.0) 581 (56.7) 1.17 (1.08 to 1.27) <0.001 1.32 (1.16 to 1.50) <0.001
Diabetes 2772 (19.2) 1045 (34.6) 342 (33.4) 2.05 (1.88 to 2.24) <0.001 1.72 (1.50 to 1.97) <0.001
Other IHD 7990 (55.3) 1509 (49.9) 486 (47.5) 0.88 (0.82 to 0.96) 0.003 0.81 (0.71 to 0.92) 0.001
Atrial fibrillation 1283 (8.9) 796 (26.3) 203 (19.8) 2.35 (2.13 to 2.60) <0.001 1.33 (1.13 to 1.57) 0.001
Chronic renal
failure
397 (2.8) 492 (16.3) 78 (7.6) 4.83 (4.21 to 5.55) <0.001 1.18 (0.92 to 1.50) 0.18
Peripheral vascular
disease
1387 (9.6) 560 (18.5) 190 (18.6) 1.57 (1.41 to 1.75) <0.001 1.49 (1.26 to 1.76) <0.001
Cerebrovascular
disease
1672 (11.6) 719 (23.8) 265 (25.9) 1.56 (1.41 to 1.73) <0.001 1.70 (1.46 to 1.97) <0.001
HF indicates heart failure; IHD, ischemic heart disease; IQR, interquartile range.
*Age- and sex adjusted.
†Adjusted for sex.
‡Adjusted for age.
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previous study of nonfatal acute coronary syndrome cases in
Western Australia,21 we observed a high rate of aspirin
discharge prescription between 1998 and 2003 (88%) and
increased rates of prescription of clopidogrel (0% to 60%),
statins (60% to 83%), b-blockers (61% to 77%), angioten-
sin-converting enzyme inhibitors/angiotensin receptor block-
ers (33% to 71%), and all 4 drug groups (10% to 50%)
(unpublished data). A 2.5-fold increase in the rate of emergent
revascularization procedures was also apparent over the
period of the present study.
Over recent decades, the incidence and 28-day case-fatal-
ity rate of AMI have improved substantially in the WA
population concordant with trends reported from other
Western countries.30–34 At the same time, new criteria for
the diagnosis of AMI on the basis of the more sensitive
troponin biomarkers have substantially increased the detec-
tion of smaller AMIs21,22,30,35 and the incidence of
non-ST-segment elevation MIs (NSTEMIs) relative to STE-
MIs.31,33,34 This may in turn contribute to a reduced risk of
subsequent HF and potentially to reduced severity of HF and
better prognosis, although the latter is contentious.36,37 The
increase in diagnosis of less severe AMIs may well have
contributed to the 50% reduction in the overall 28-day
case-fatality rate and incidence of HF after AMI observed in
the present study. However, the decline in 28-day case-fatal-
ity occurred largely in patients without HF, whereas patients
with concurrent HF in the most recent calendar period
remained at signiﬁcantly higher risk of 28-day mortality than
those without concurrent HF (15.9% versus 3.2%).
Our extended survival analysis conﬁrmed that survivors of
AMI complicated by HF, whether it was early or late onset,
continued to have a high long-term mortality hazard, a point
that has also been highlighted by other studies.13–15,27,28 In
fact, our landmark analysis suggested that although early
survival gains have occurred in patients developing HF after
AMI, this may be counterbalanced by an increased adjusted
hazard for death between 90 days and 1 year. Thus, incident
HF remains one of the most powerful predictors of late
mortality after AMI. Actually, by the last calendar period,
mortality was 3.2% at 28 days and 3.6% at 1 year in 28-day
AMI survivors without HF, whereas mortality was 15.9% and
15.3%, respectively, for those with concurrent HF. It is
therefore likely that most of the survival gains to be expected
in the future will have to come from earlier and more
aggressive application of guideline-recommended treatments
in AMI patients at risk of HF as well as enhanced secondary
prevention after HF occurrence.
Although we are unable to account for the propensity to
undergo revascularization, it appears that an invasive strategy
with PCI performed during initial AMI admission is associated
with lower adjusted odds of death at 28 days and lower
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regardless of HF occurrence. This is in keeping with a
meta-analysis of randomized clinical trials that showed that an
invasive management strategy was superior to an initially
conservative strategy among NSTEMI acute coronary syn-
drome cases, and that the beneﬁt was greatest for patients at
highest risk.7 Yet, despite a favorable beneﬁt-to-risk ratio,
revascularization procedures were performed less frequently
in our AMI subcohort with HF than in those without HF. Other
observational studies have also shown that the occurrence of
HF after AMI was a strong correlate of a conservative
management strategy and underuse of revascularization
procedures.10,16,38–40 Furthermore, these same studies have
also reported lower use of evidence-based pharmacotherapies
including aspirin, heparin, b-blockers, statins, and ﬁbrinolytics
to the disadvantage of AMI cases complicated by
HF.10,16,26,29,38,40 Reasons for the disparities in treatment
are unclear. However, patients at risk of HF after AMI are
generally older and more often female and have a greater
burden of comorbid conditions including diabetes and renal
failure, which are generally predictive of a lower use of
invasive interventions and evidence-based pharmacotherapies
after AMI.10,26,39,41 Therefore, reducing the apparent evi-
dence-treatment gap in the pharmacological and invasive
management of AMI patients complicated by HF is a high
priority.
Study Strengths and Limitations
Our study is a large contemporary population-based study of
patients admitted with a ﬁrst AMI. The availability of a
person-based record linkage means that we could determine
those persons without prior HF who had a ﬁrst AMI admission
and enabled ascertainment of major comorbidities and
invasive procedures that are essential for risk adjustment.
An HMD principal diagnosis of AMI and HF has also been
previously validated demonstrating good accuracy.19,20,30
However, we have not performed a validation study of HF
as a secondary diagnosis in the HMD. Nevertheless, there are
several limitations. We did not assess for trends in the
prevalence of STEMI and NSTEMI, as this may not be accurate
using administrative coding. The diagnostic criteria for AMI,
which incorporated the more sensitive troponin biomarkers,
changed over the study period,21,22,29 and we cannot
determine whether the observed trend in the overall AMI
case-fatality rate and HF incidence is related to a true trend in
disease development or a reﬂection of smaller AMIs being
included in the analysis in the latter period. However, even if
smaller AMIs were included, that a concurrent or late-onset
HF diagnosis was associated with persistently high crude
mortality deserves close attention. We were unable to adjust
for clinical severity of HF, but this does not diminish the
importance of a recorded diagnosis of HF in the medical
record, which we found to be associated with a 2- to 3-fold
increased adjusted risk of 28-day and 1-year mortality. We
could not assess for disparities in treatment between AMI
patients (except for revascularization procedures) or changes
in prescription of evidence-based pharmacotherapies over the
period, except for that observed in a subset of nonfatal acute
coronary syndrome cases between 1998 and 2003.21 There
was a potential immortal time bias when assessing the effect
Table 4. Multivariable-Adjusted Hazard of Death Between 28 Days and 1 Year, and Between 90 Days and 1 Year According to
Calendar Periods and Occurrence of Heart Failure
Hazards Ratio for Death at 1 Year in 28-Day
Survivors*
Hazards Ratio for Death at 1 Year in 90-Day
Survivors†
All Patients (n=17 071) All Patients (n=16 795)
HR (95% CI) P Value HR (95% CI) P Value
Variable
No HF 1.00 1.00
Concurrent HF 2.23 (1.93 to 2.58) <0.001 —
HF within 90 days — 2.66 (2.24 to 3.15) <0.001
Calendar period
1996–1998 1.00 1.00
1999–2001 1.07 (0.89 to 1.29) 0.47 1.20 (0.96 to 1.49) 0.12
2002–2004 1.16 (0.96 to 1.39) 0.12 1.30 (1.04 to 1.62) 0.02
2005–2007 1.10 (0.89 to 1.35) 0.38 1.34 (1.04 to 1.72) 0.02
CABG indicates coronary artery bypass grafting; CI, conﬁdence interval; HF, heart failure; HR, hazard ratio; IHD, ischemic heart disease; PCI, percutaneous coronary intervention.
*Cox regression model was adjusted for age, sex, concurrent HF, diabetes, chronic renal failure, other IHD, atrial ﬁbrillation, peripheral vascular disease, cerebrovascular disease, Charlson
comorbidity index, history of PCI or CABG in the last 10 years, and PCI or CABG within index admission.
†Landmark analysis at 90 days with the Cox regression model adjusted for age, sex, HF within 90 days, diabetes, chronic renal failure, other IHD, atrial ﬁbrillation, peripheral vascular
disease, cerebrovascular disease, Charlson comorbidity index, history of PCI or CABG in the last 10 years, and PCI or CABG within index admission.
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of revascularization on 28-day mortality, but this was avoided
in the 1-year landmark analysis. Because this is an observa-
tional study, care must be taken not to attribute a causal
effect to the observed associations.
Conclusions
Despite encouraging declines in the incidence of HF compli-
cating AMI over recent decades, it remains a common
problem with high mortality. Concerted efforts at early
detection of these high-risk patients, reducing disparities in
guideline-recommended treatments and optimal secondary
prevention, are needed given the lack of improvement in their
long-term prognosis.
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